Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shunaoxin is a Traditional Chinese Medicine (TCM) formulation, most commonly administered as dripping pills, developed by the Sixth Chinese Medicine Factory of Tianjin Zhongxin Pharmaceutical Group (now Tianjin Pharmaceutical Da Ren Tang Group). It is composed of concentrated extracts from *Ligusticum chuanxiong* and *Lycium barbarum*. The medication is primarily indicated for the treatment of cerebrovascular conditions such as cerebral infarction, cerebral arteriosclerosis, and associated symptoms including headache, dizziness, and memory loss. Its therapeutic effects are attributed to its ability to improve cerebral microcirculation, inhibit platelet aggregation, and provide neuroprotection against ischemic injury. Bioactive components like ligustrazine and ferulic acid contribute to its vasodilatory and antioxidant properties.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Shunaoxin.